Neuronetics reports Q3 EPS (13c) vs. (44c) last year

Reports Q3 revenue $37.3M, consensus $37.85M. “Our third quarter results reflect continued progress as we integrate and optimize our combined operations,” said Keith Sullivan, President and Chief Executive Officer of Neuronetics (STIM) “On an adjusted pro forma basis, we delivered 11% revenue growth, with particularly strong performance from our Greenbrook clinics. We are finding opportunities to improve efficiency across both the Greenbrook clinic network and NeuroStar business, taking advantage of our combined scale, which is driving meaningful progress toward cash flow positivity. The momentum we’re building gives us confidence in our ability to deliver value for both patients and shareholders.”